Core Points - Jimin Health's stock price increased by 2.08% on November 11, reaching 10.33 CNY per share, with a market capitalization of 5.424 billion CNY [1] - The company has seen a year-to-date stock price increase of 52.14%, with a recent 5-day increase of 3.20% and a 60-day increase of 45.90% [1] - Jimin Health has appeared on the trading leaderboard 13 times this year, with the latest occurrence on September 11, where it recorded a net purchase of 66.0795 million CNY [1][2] Financial Performance - For the period from January to September 2025, Jimin Health reported a revenue of 545 million CNY, a year-on-year decrease of 20.21%, and a net profit of -77.1504 million CNY, a decrease of 371.51% [2] - The company has distributed a total of 127 million CNY in dividends since its A-share listing, with 10.7447 million CNY distributed in the last three years [3] Shareholder Information - As of September 30, Jimin Health had 58,100 shareholders, an increase of 107% from the previous period, with an average of 9,035 circulating shares per shareholder, a decrease of 51.69% [2] Business Overview - Jimin Health, established on December 24, 1996, and listed on February 17, 2015, is primarily engaged in the research, production, and sales of medical devices, medical services, and large-volume intravenous products [1] - The company's revenue composition includes 52.07% from pharmaceutical manufacturing, 46.01% from medical services, 1.54% from pharmaceutical trading, and 0.38% from other sources [1] Industry Classification - Jimin Health is classified under the pharmaceutical and biological industry, specifically in medical devices and consumables, with involvement in innovative drugs, cell therapy, in vitro diagnostics, antigen testing, and medical devices [2]

Core Viewpoint - Jimin Health announced on November 5 that the company will consider share buybacks based on market conditions [2] Group 1 - The company is actively engaging with investors through an interactive platform [2] - The decision to repurchase shares will be contingent on market circumstances [2]

Group 1 - The company plans to leverage the innovative policies of the Boao Lecheng Pilot Zone in Hainan to enhance external cooperation [2] - The company aims to increase investment in the research and development of innovative drugs [2] - The company intends to develop the Boao International Hospital into a high-level clinical research center and translational medicine platform [2]

Core Viewpoint - The medical device sector is experiencing positive momentum, with significant stock price increases for key companies and a notable rise in the medical device ETF, indicating strong investor interest and potential growth in the industry [1][3]. Company Performance - The medical device ETF (159883) rose by 0.96%, reflecting a broader market trend in the medical device sector [1]. - Key stocks such as BeiGene (000710) increased by over 6%, Lepu Medical (300003) by over 5%, and other companies like Spring Medical (688236) and Jimin Health (603222) also saw gains [1][2]. Product Development - Lepu Medical announced the approval of its rechargeable implantable deep brain stimulation system by the National Medical Products Administration, marking a significant achievement in the neuro-regulation field [2][3]. - This product aims to provide new treatment options for Parkinson's disease patients, enhancing the company's competitive edge in the medical device market [3]. Market Trends - The medical device sector is currently viewed as undervalued, with multiple growth drivers identified, including government support for advanced technologies like brain-machine interfaces [3]. - Domestic companies are actively pursuing innovation and expanding into overseas markets, driven by strategies for self-sufficiency and international growth [3]. ETF Insights - The medical device ETF (159883) is the largest in the A-share market, tracking the CSI All-Share Medical Device Index, which encompasses various segments including medical equipment and consumables [4]. - The ETF's significant growth, with an increase of 4.8 billion in shares and over 120% rise in value during the third quarter, highlights strong investor confidence in the sector [1][4].

Core Viewpoint - The A-share market experienced a collective decline, with the Shanghai Composite Index down 0.44%, Shenzhen Component Index down 0.84%, and ChiNext Index down 1.04. The medical device ETF showed resilience, increasing by 1.00% amid mixed performances from constituent stocks, highlighting potential growth in the medical device sector driven by regulatory approvals and market trends [1]. Group 1: Market Performance - The medical device ETF (562600) rose by 1.00%, with the latest price at 0.91 yuan and a trading volume of 0.14 billion yuan, reflecting a turnover rate of 6.14% [1]. - The medical device ETF has seen a scale increase of 0.42 billion yuan over the past week, reaching a new high since its launch [2]. - The medical device ETF has recorded net inflows for six consecutive trading days, with a maximum single-day net inflow of 0.15 billion yuan, totaling 0.48 billion yuan in net inflows [2]. Group 2: Company Developments - Lepu Medical's subsidiary received regulatory approval for a rechargeable implantable deep brain stimulation (DBS) system, marking a significant breakthrough in China's neuroregulation field and expected to enhance performance while mitigating the impact of centralized procurement [1]. - The global DBS market is anticipated to grow rapidly, with an increasing trend towards alternatives [1]. Group 3: Valuation and Sector Composition - The latest price-to-earnings ratio (PE-TTM) for the medical device ETF is 47.48, which is below the 63.83% percentile of the past decade, indicating a moderate valuation [2]. - The ETF's index weight is heavily concentrated in the pharmaceutical and biological sectors (95.14%), with smaller allocations to beauty care (4.60%) and light manufacturing (0.26%) [2]. - Within the secondary industry classification, the ETF's index weight is primarily in medical devices (90.28%), followed by medical services (4.36%) and medical beauty (3.30%) [2].

Core Viewpoint - The company has announced its third-quarter financial report, emphasizing the accuracy and completeness of the information provided by its board and management, while also detailing its share repurchase plan and ongoing legal issues related to a fraud case [2][6][7]. Financial Data - The financial report for the third quarter is unaudited, and the company has provided key financial data and indicators in RMB [3][8]. - As of September 30, 2025, the company has repurchased a total of 2,005,500 shares, with a total expenditure of 12.089 million RMB (excluding transaction fees) [7]. Share Repurchase Plan - The company plans to repurchase shares using its own funds through centralized bidding, with a maximum price of 10.00 RMB per share and a total repurchase amount between 100 million RMB and 200 million RMB, to be completed within 12 months from the board's approval [6][7]. Legal Issues - The company is currently facing 14 lawsuits from primary distributors involving a total of 69.5026 million RMB, and 10 lawsuits from secondary distributors involving 17.0766 million RMB, related to a case of forgery involving a former employee [7].

（编辑 姚尧） 证券日报网讯 10月31日晚间，济民健康发布公告称，公司于近日收到双鸽集团有限公司（以下简称"双 鸽集团"）通知，双鸽集团在浙商银行股份有限公司台州分行质押的17，640，000股股份办理了解除质 押手续。 ...

Core Points - Jimin Health announced that it will not implement a share buyback in October 2025 [2] Group 1 - The company released an announcement on October 31 regarding its decision on share repurchase [2]

Group 1 - The core point of the news is that Jimin Health (SH 603222) announced the release of 17.64 million shares from pledge by its major shareholder, Shuangge Group, which holds approximately 123 million shares, accounting for 23.38% of the total share capital [1] - After the release of the pledge, Shuangge Group has a total of 76.5 million shares pledged, which is 62.32% of its holdings and 14.57% of the total share capital [1] - The combined shareholding of Shuangge Group and its concerted parties is about 229 million shares, representing 43.52% of the total share capital [1] Group 2 - As of the announcement, Jimin Health's market capitalization is 5.4 billion yuan [2] - For the first half of 2025, Jimin Health's revenue composition is as follows: 52.07% from the pharmaceutical manufacturing sector, 46.01% from the medical services sector, 1.54% from pharmaceutical trading, and 0.38% from other businesses [1]

证券代码：603222 证券简称：济民健康 公告编号：2025-050 济民健康管理股份有限公司 关于控股股东部分股份解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 双鸽集团持有公司股份数量为 122,748,520 股，占公司总股本的 23.38%。 本次解除质押数量为 17,640,000 股，截止本次解质完成，双鸽集团累计质押股 份数量为76,500,000股，占其所持股份数量比例62.32%，占公司总股本的14.57%。 ● 双鸽集团及其一致行动人合计持有公司股份 228,557,540 股，占公司总 股本的 43.52%。本次股份解除质押后，控股股东及其一致行动人累计质押股份 140,900,000 股，占其所持股份的 61.65%，占公司总股本的 26.83%。 公司于近日收到双鸽集团有限公司（以下简称"双鸽集团"）通知，双鸽集 团在浙商银行股份有限公司台州分行质押的 17,640,000 股股份办理了解除质押 手续，具体情况如下： 济民健康管理股份有限公司董事会 | 股东名称 ...